financetom
Business
financetom
/
Business
/
T. Rowe Price Group August Assets Under Management Rise Month Over Month
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
T. Rowe Price Group August Assets Under Management Rise Month Over Month
Sep 11, 2025 6:21 AM

09:13 AM EDT, 09/11/2025 (MT Newswires) -- T. Rowe Price ( TROW ) reported preliminary assets under management Thursday of $1.729 trillion as of Aug 31, up from $1.703 trillion in the previous month.

The company said its equity assets rose to $867 billion at the end of August from $859 billion as of July 31, and multi-assets increased to $602 billion from $586 billion.

Fixed-income assets, including money market, rose to $205 billion from $202 billion, while alternative assets fell to $55 billion from $56 billion, the investment management firm said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
IDEX Corp beats Q3 estimates on strong demand for health and science products
IDEX Corp beats Q3 estimates on strong demand for health and science products
Oct 29, 2025
Oct 29 (Reuters) - Industrial equipment maker IDEX Corp ( IEX ) on Wednesday posted a stronger-than-expected profit and revenue for the third quarter, helped by a protracted recovery in its health and science product lines. Sales in the health and science technology segment rose 22% from a year earlier, as customers continued to restock after working through the large...
Anavex Life Sciences' Alzheimer's Drug Candidate Shows Continued Long-Term Benefit Versus Control Group
Anavex Life Sciences' Alzheimer's Drug Candidate Shows Continued Long-Term Benefit Versus Control Group
Oct 29, 2025
On Wednesday, Anavex Life Sciences Corp. ( AVXL ) announced new findings for blarcamesine, an oral small molecule for early Alzheimer's disease. AVXL stock is taking a breather. Get the market research here. New data demonstrate continued long-term benefit from oral blarcamesine compared to the decline observed in the Alzheimer's Disease Neuroimaging Initiative (ADNI) control group. Data Externally matched control...
Garmin's Fiscal Q3 Adjusted Earnings Flat, Revenue Rises; Fiscal 2025 Adjusted EPS Guidance Raised
Garmin's Fiscal Q3 Adjusted Earnings Flat, Revenue Rises; Fiscal 2025 Adjusted EPS Guidance Raised
Oct 29, 2025
07:31 AM EDT, 10/29/2025 (MT Newswires) -- Garmin ( GRMN ) reported fiscal Q3 adjusted earnings Wednesday of $1.99 per diluted share, unchanged from a year earlier. Analysts polled by FactSet expected $1.99. Net sales for the fiscal quarter ended Sept. 27 were $1.77 billion, up from $1.59 billion a year earlier. Analysts polled by FactSet expected $1.78 billion. The...
Anavex Life Sciences' Alzheimer's Drug Candidate Shows Continued Long-Term Benefit Versus Control Group
Anavex Life Sciences' Alzheimer's Drug Candidate Shows Continued Long-Term Benefit Versus Control Group
Oct 29, 2025
On Wednesday, Anavex Life Sciences Corp. ( AVXL ) announced new findings for blarcamesine, an oral small molecule for early Alzheimer's disease. AVXL stock is taking a breather. Get the market research here. New data demonstrate continued long-term benefit from oral blarcamesine compared to the decline observed in the Alzheimer's Disease Neuroimaging Initiative (ADNI) control group. Data Externally matched control...
Copyright 2023-2026 - www.financetom.com All Rights Reserved